Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC raised its position in Biodesix, Inc. (NASDAQ:BDSX) by 385.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,024 shares of the company’s stock after purchasing an additional 40,524 shares during the period. Cubist Systematic Strategies LLC’s holdings in Biodesix were worth $78,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of BDSX. Samjo Management LLC acquired a new stake in shares of Biodesix in the 4th quarter valued at $3,790,000. Susquehanna International Group LLP raised its holdings in shares of Biodesix by 769.8% in the 4th quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company’s stock valued at $1,707,000 after purchasing an additional 987,475 shares in the last quarter. Silverarc Capital Management LLC raised its holdings in shares of Biodesix by 21.7% in the 4th quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock valued at $6,628,000 after purchasing an additional 771,187 shares in the last quarter. AIGH Capital Management LLC raised its holdings in shares of Biodesix by 8.8% in the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock valued at $9,455,000 after purchasing an additional 500,000 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its holdings in shares of Biodesix by 46.3% in the 4th quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company’s stock valued at $1,622,000 after purchasing an additional 335,429 shares in the last quarter. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Biodesix Trading Down 0.1%

NASDAQ BDSX opened at $0.30 on Tuesday. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. The firm’s fifty day moving average price is $0.56 and its 200 day moving average price is $0.97. The company has a market capitalization of $44.12 million, a price-to-earnings ratio of -0.77 and a beta of 1.18. Biodesix, Inc. has a 12 month low of $0.17 and a 12 month high of $2.04.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Tuesday, May 13th. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $17.96 million for the quarter, compared to the consensus estimate of $19.50 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. On average, sell-side analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. William Blair restated a “market perform” rating on shares of Biodesix in a report on Wednesday, May 14th. Canaccord Genuity Group dropped their target price on shares of Biodesix from $2.50 to $1.50 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Lake Street Capital dropped their target price on shares of Biodesix from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Finally, Craig Hallum dropped their target price on shares of Biodesix from $3.00 to $1.50 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $2.00.

Biodesix Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.